Celina Dubin

Moderate-to-severe atopic dermatitis (AD) has been associated with significant disease burden and systemic abnormalities and often requires systemic treatments. Currently, safe and effective oral systemic treatments for moderate-to-severe AD are not yet available. ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T2/T22/T17/...

Our approach has the potential to facilitate future development of a personalized medicine approach in AD, and identify the best treatments for individual phenotypes, on the basis of immune and barrier profiles. For the full version of the Study: https://www.jacionline.org/article/S0091-6749(20)30039-7/fulltext

Chronic hand eczema (C.H.E) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Originally published in Pub Med: https://pubmed.ncbi.nlm.nih.gov/33408476/

Atopic dermatitis (AD) is the most common inflammatory skin disease. It has a complex pathophysiology, with a combination of immune dysregulation and intrinsic barrier defects driving cutaneous inflammation and allergic symptomatology. See the original Article here: https://www.researchgate.net/publication/352278907_The_IL-4_IL-13_and_IL-31_pathways_in_atopic_dermatitis By Celina Dubin, Ester Del...

The American Red Cross has recalled 164 lots of antihemophilic factor (AHF) and albumin, due to the potential contamination of this product with the causative agent of Creutzfeld-Jakob disease (CJD).